Cell death is an inherent process that is required for the proper wiring of the nervous system. Studies over the last four decades have shown that, in a parallel developmental pathway, axons and dendrites are eliminated without the death of the neuron. This developmentally regulated 'axonal death' results in neuronal remodeling, which is an essential mechanism to sculpt neuronal networks in both vertebrates and invertebrates. Studies across various organisms have demonstrated that a conserved strategy in the formation of adult neuronal circuitry often involves generating too many connections, most of which are later eliminated with high temporal and spatial resolution. Can neuronal remodeling be regarded as developmentally and spatially regulated neurodegeneration? It has been previously speculated that injury-induced degeneration (Wallerian degeneration) shares some molecular features with 'dying back' neurodegenerative diseases. In this opinion piece, we examine the similarities and differences between the mechanisms regulating neuronal remodeling and those being perturbed in dying back neurodegenerative diseases. We focus primarily on amyotrophic lateral sclerosis and peripheral neuropathies and highlight possible shared pathways and mechanisms. While mechanistic data are only just beginning to emerge, and despite the inherent differences between disease-oriented and developmental processes, we believe that some of the similarities between these developmental and disease-initiated degeneration processes warrant closer collaborations and crosstalk between these different fields.
Introduction
Developmentally regulated neuronal cell death plays important roles in the development of the vertebrate and invertebrate nervous systems [1] [2] [3] and is detected at the final stages of neurodegenerative diseases. Accumulating evidence highlights another regressive process during development that resembles 'axonal death' but does not involve the death of the neuron [4] [5] [6] . Axon, dendrite and synapse elimination, resulting in neuronal remodeling of the neural circuit, was found to be a conserved strategy to refine and sculpt neural circuits during the assembly of vertebrate and invertebrate nervous systems. Remodeling includes the elimination of exuberant or improper connections and is often followed by stabilization or regrowth of new connections to form the adult-specific neural circuit (Figure 1, top) . While pruning of neuronal connections without the death of the neuron was first discovered only about 40 years ago [4] [5] [6] , a re-examination of Ramon y Cajal's images from more than a century ago suggests that he too identified this process in avian Purkinje and mammalian granule cells and termed it 'process resorption' [7, 8] . Following four decades of research and the discovery of a wide variety of neural circuits in different organisms that undergo remodeling, the emerging picture is that a broad set of neural circuits in the central and peripheral nervous systems develop by initially forming too many connections that are then refined by various strategies of neuronal remodeling. Defects in remodeling have been attributed to a variety of psychoneurological conditions, including autism, schizophrenia and synesthesia [9] [10] [11] [12] , although a clear causality has not yet been established and the underlying mechanisms are not well understood.
In this article we chose not to review the current status of neuronal remodeling, as several good reviews have been recently published on this topic [7, [13] [14] [15] . Instead, we decided to explore the idea that understanding the mechanism underlying neuronal remodeling could provide us with insights into the mechanisms of various neurodegenerative diseases. Could neuronal remodeling be perceived as developmentally and spatially regulated neurodegeneration? If this were true, then perhaps some of the machinery that is required to dismantle axons and dendrites in a regulated manner during development is hijacked and exploited due to various insults during neurodegeneration, especially in 'dying back' neurodegenerative diseases in which the breakdown of the axons occurs before and even in the absence of cell death.
Indeed, Raff and colleagues [16] have previously speculated that axon pruning and injury-induced axon degeneration (Wallerian degeneration) share molecular similarities with dying back neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), neuropathies, and spinocerebellar disorders, e.g. Friedreich's ataxia. Up until now, this speculation has mostly been tested by exploring whether expression of Wld s (Wallerian degeneration slow) -a fusion protein between the ubiquitin ligase Ube4b and nicotinamide mononucleotide adenylyltransferase type 1 (Nmnat1) that slows Wallerian degenerationcan slow disease onset or progression in different models of neurodegeneration. Results have been mixed: Wld s indeed slows motor neuron loss in some models of motor neuron disease [17] and neuropathy [18] , but not in all [19, 20] . Interestingly, Wld s is not able to delay onset or slow disease progression in ALS models [21, 22] . Recent progress in our understanding of Wallerian degeneration and its relevance to disease has been reviewed elsewhere [19, 20, [23] [24] [25] and we will therefore not discuss it in depth.
Saxena and Caroni [26] revisited and extended the hypothesis proposed by Raff. While they highlighted a striking similarity in the sequence of cellular events involved in developmental remodeling, Wallerian degeneration and dying back neurodegenerative diseases, Saxena and Caroni also pointed out some important differences. In essence, they raised a speculative model in which the mechanisms that regulate these three major forms of axon elimination diverge and converge on multiple points. They proposed that the initiation of axon degeneration is unique to each developmental or disease condition, but that the axon dismantling itself involves conserved mechanisms. While this model is highly attractive, hard supporting evidence is still lacking.
In this article we further examine whether insights from the field of developmental neuronal remodeling can complement the progress from the Wallerian degeneration field and enrich our understanding of pathological neurodegeneration. Therefore, we examine here the possible roles of 'remodeling genes and pathways' in dying back neurodegenerative diseases, primarily focusing on ALS and peripheral neuropathy. Although mechanistic insights are only just beginning to emerge, and despite the inherent differences between events taking place during disease and development, we believe that the similarities as well as differences warrant closer collaborations and crosstalk between these different fields.
Dying Back Neurodegeneration
It has long been known that the onset of several neurodegenerative diseases begins with axonal atrophy, which gradually (Top) Restricted axonal fragmentation serves as a key mechanism to prune exuberant connections during development. The axonal fragments are engulfed by phagocytic cells such as glia or epidermal cells. Following pruning, axons often regrow to form new connections in a mechanism that resembles axonal regeneration. (Bottom) Genetic lesions or toxic conditions induce axonal loss in a dying back fashion from the target. Dying back is usually accompanied by gliosis and in some cases ends in neuronal cell death.
affects the viability of the neuron (Figure 1 , bottom). One of the first investigators to formulate this notion, leading to the categorization of several conditions as dying back neurodegenerative diseases, was Cavanagh [27] , who wrote: ''.this is in general a slow atrophy affecting individual neurons and their fibers at various moments in time, and the clinical consequences are seen only when the compensatory forces begin to fail in the face of cumulative nerve fiber damage''. He highlighted the dying back phenotype in neurodegenerative conditions that result from exposure to neurotoxins, such as tricresyl phosphate, and also in diseases including ALS, neuropathies, Friedreich's ataxia and Werdnig-Hoffmann's disease, now known as spinal muscular atrophy type I. Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig's disease, is a devastating and incurable adult onset neurodegenerative disease. ALS is characterized by rapidly progressive muscular atrophy ('amyotrophic') and scarring of tissues in the lateral spinal cord ('lateral sclerosis'), ultimately resulting in paralysis and death from respiratory failure. The initial symptoms are usually detected in the fifth or sixth decade of life and the average time until death is around 2-3 years. Studies of autopsies from ALS patients as well as ALS mouse models suggest that this slow progression of the symptoms is due, at least in part, to the fact that neurodegenerative events begin in distal axons and slowly progress to the cell bodies [28, 29] . The vast majority (90%) of ALS cases are sporadic (sometimes also called SALS) while the remaining 10% are inherited and thus called familial ALS (FALS) [30] [31] [32] .
Mutations in the superoxide dismutase 1 (SOD1) gene were the first, and until quite recently the only, identified causal mutations driving ALS in human patients and in model animals [33, 34] . In humans, SOD1 mutations, inherited in a dominant fashion, are responsible for 12% of familial cases but only 1% of sporadic ALS cases. Despite many decades of intensive research, including the generation of many model animals, the precise mechanism by which mutant SOD1 drives motor neuron disease and even whether it functions in a cell-autonomous or non-cellautonomous manner are not well understood.
Following 15 years in which mutations in SOD1 represented the only genetic lesion linked with ALS, the past 10 years have seen an explosion in our understanding of ALS genetics: mutations in around nine genes have been identified in 68% of familial and 11% of sporadic ALS cases [30] [31] [32] . The gene that is by far the most implicated in ALS is C9ORF72, encoding a protein with an unknown function, in which a hexanucleotide repeat expansion is dominantly inherited [35, 36] . These expansions are likely the cause of 40% of familial and 7% of sporadic ALS, as well as 25% of familial fronto-temporal dementia (FTD), thereby providing a genetic link between ALS and FTD [37] .
Taken together, while there has been tremendous progress in our understanding of the genetic basis for ALS, the mechanisms driving motor neuron axonopathy and death remain mostly unclear. The vast majority of the mutations are dominantly inherited and therefore could result in gain-of-function defects, which are often difficult to understand mechanistically. Peripheral Neuropathies Peripheral nerve degeneration (peripheral neuropathy) is a widespread neuronal disorder that is largely manifested by the loss of sensory and/or motor axons of the peripheral nervous system. This loss leads to ineffective communication of peripheral organs with the central nervous system. Patients with peripheral neuropathies exhibit a variety of symptoms, which include but are not limited to abnormal pain and touch sensations, weakness, and motor deficits as a result of muscle atrophy. Peripheral neuropathies can be divided into hereditary neuropathies and acquired neuropathies, which are triggered by other systemic diseases or exposure to drugs, chemicals and viral infections [25, 38] . Diabetes is the most common cause of peripheral neuropathy worldwide, and also the disease that shows the highest association with acquired neuropathies [39] . The most common form of hereditary sensory and motor neuropathies is CharcotMarie-Tooth (CMT) disease, which is composed of a genetically heterogeneous collective assembly of peripheral nervous system disorders. Moreover, the clinical symptoms of CMT vary in severity and age of onset, even among members of the same family. CMT is classified into several types according to electrophysiological and nerve biopsy measurements, and mode of genetic inheritance. The most frequent types of CMT are CMT1, defined as a demyelinating neuropathy with clear histological evidence of de-and re-myelination, and CMT2, defined as axonal neuropathy [40, 41] . Importantly, almost all types of neuropathies are chronic but exhibit a slow, progressive deterioration in symptoms as a result of dying back axon degeneration.
Common and Divergent Mechanisms
In the main section of this opinion piece, we would like to discuss the potential roles of specific pathways in both developmental remodeling and dying back neurodegenerative diseases. Figure 2 includes a schematic representation of the genes and pathways discussed throughout this section.
Role of Trophic Factors
During development the neurotrophin family of trophic factors, of which nerve growth factor (NGF) is the founding member, regulates various aspects of neuronal development. In the peripheral nervous system, these trophic factors are produced in limited amounts at peripheral targets and operate through retrograde signaling or locally at the tip of the axons to control multiple aspects of peripheral nervous system development, including cell survival, neuronal specification and target innervation [42] . Studies using in vitro compartmentalized chambers of sensory axons have demonstrated that local axonal deprivation of trophic support elicits restricted axonal degeneration, which morphologically recapitulates axonal pruning [43] . Importantly, several molecular regulators of axonal degeneration that were discovered in this in vitro setting were also shown to modulate developmental pruning in the central nervous system [44] .
More recently, it was demonstrated that male-specific developmental masking of brain-derived neurotrophic factor (BDNF) signaling leads to pruning of sensory axons from the mammary gland, thereby establishing a sexually dimorphic circuit [45] .
Neurotrophins and other trophic factors are also expressed by adult target tissues and are thought to be required for axonal maintenance and sprouting following injury [46, 47] . Could decreased levels of neurotrophins be an early cause of dying back neurodegenerative diseases? While not much is known mechanistically, it is interesting to mention that several studies have demonstrated a reduction in NGF expression in the skin of diabetic patients, suggesting that a reduction in trophic support is at least part of the reason that nociceptive axons, which innervate the skin, are lost during the course of diabetes [48, 49] . While these studies did not determine causality, these observations raised high hopes that NGF administration could serve as a potential treatment. Unfortunately, administration of NGF resulted in severe side effects that led to the cessation of the clinical trials [50] . Although reduction in trophic support was not reported in mouse models of ALS, intramuscular application of ciliary neurotrophic factor (CNTF) delayed but did not prevent axonal loss in the SOD1 mutant mouse model of ALS [51] . This study suggests that trophic signaling can counter the degenerative process and that reduction in axonal transport and trophic retrograde signaling may be one factor that facilitates axonal loss in the initial phase of the disease. Protein Degradation Developmental neuronal remodeling involves the activation of an axon or dendrite disintegration and elimination program, which likely involves degradation of proteins, cytoskeleton and membranes. Experiments in flies have shown that the ubiquitin proteasome system (UPS) is required for axonal pruning of mushroom body g neurons, which are part of a structure in the central nervous system required for learning and memory, and also for dendrite pruning of the peripheral class IV dendritic arborization (da) sensory neurons that cover the larval body wall. Overexpression of the yeast ubiquitin carboxyl-terminal hydrolase 2 (UBP2), an enzyme that reverses the addition of ubiquitin molecules, inhibited axon pruning in the mushroom body [52] . Similarly, mutations in genes that encode proteins belonging to the UPS, such as ubiquitin-activating enzyme E1 (UBA1) and proteasome subunits, essentially blocked pruning of mushroom body axons [52] and of da dendrites in a cell-autonomous manner [53, 54] . While we know of at least two targets for the UPS in the context of pruning in da neurons -the Drosophila inhibitor of apoptosis (DIAP1) [53] and components of the insulin pathway [55] -we do not know which proteins are degraded during developmental pruning of mushroom body axons [13] . Our knowledge of the role of the UPS in remodeling of mammalian neurons is limited to an in vitro system of remodeling in which cultured primary neurons (usually from the dorsal root ganglion) undergo axon elimination following trophic deprivation of the axons but not the cell bodies [43] . Indeed, pharmacological inhibition of the UPS inhibited axon elimination in dorsal root ganglion cultures following trophic deprivation [56] .
Ubiquitin-mediated protein degradation is also involved in ALS. Mutations in at least three UPS-related genes, encoding valosin-containing protein (VCP [57] ), ubiquilin 2 (UBQLN2 [58] ) and sequestosome 1 (SQSTM1 [59] ), were found in ALS patients, but the mechanisms by which they cause the disease is not well understood. The fact that mutations in the UPS promote ALS pathology and at the same time inhibit developmental pruning seems counterintuitive. However, whether the disease-causing mutations result in loss of function is still not clear. For example, ubiquilin 2, a protein that is important in linking ubiquitin ligases to the proteasome, is mutated in familial ALS where it is inherited in an X-linked dominant fashion. The prevailing dogma is that the ALS-associated mutations in ubiquilin 2 result in loss of function, leading to the formation of toxic aggregates [32] comprising proteins such as TDP-43, foci of which are associated with many ALS cases. However, a recent study has found that, while expression of mutant ubiquilin 2 in rats resulted in ALS-like phenotypes, the loss of endogenous ubiquilin 2 did not [60] , suggesting that the isolated mutations manifested a gain-of-function effect. Remarkably, Pun et al. [51] have shown that axon degeneration in a SOD1 mouse model requires the UPS: these authors were able to block SOD1-mediated motor neuron degeneration by applying UPS inhibitors even at fairly late stages, when the application of trophic factors (see previous section) was not sufficient to alleviate degeneration. These experiments clearly demonstrate that the axon destruction phase, at least in the SOD1 mouse model, depends on an intact UPS. These data might also hint that ALS-associated mutations in UPS genes likely result in gain-of-function defects, but more experiments are necessary to support this speculative idea.
The ALS-associated protein VCP, an AAA-ATPase, is known to interact with ubiquitinated proteins and process them for proteasome degradation, autophagy or endocytosis [61] . However, ALS patient-derived fibroblasts containing pathogenic VCP Figure 2 . Major pathways that underlie axonal pruning and dying back neurodegeneration.
Illustration of the main pathways that control developmental axon pruning and axon degeneration by dying back: see text for details. Blue, red and purple text: genes and pathways involved in dying back neurodegeneration (blue), developmental neuronal remodeling (red) or both (purple). Ub, ubiquitin; UPS, ubiquitin proteasome system; TGFb, transforming growth factor b; ESCRT, endosomal sorting complexes required for transport.
mutations were found to exhibit reduced ATP levels, caused by mitochondrial uncoupling [62] . VCP has been suggested to affect mitochondrial function by promoting degradation of depolarized mitochondria [63] . Therefore, the precise mechanism by which mutations in VCP cause ALS, and even whether this involves a gain or loss of function, is not well understood. Interestingly, however, mutations in VCP also affect dendrite pruning in Drosophila.
By manipulating the levels of VCP in Drosophila sensory neurons, Rumpf et al. [64] have shown that, while a strong reduction in VCP results in cell death, a moderate reduction results in the accumulation of ubiquitinated proteins, including DIAP1, whose degradation is required for dendrite pruning of da neurons [53] . Thus, VCP-depleted da neurons do not undergo normal dendrite pruning. In a follow-up study the authors found that VCP also affects, via an unknown mechanism, the splicing of various proteins, including the large cytoskeletal protein MICAL, which is required for pruning [65, 66] . Thus, VCP might affect pruning of da dendrites by various mechanisms, which are at least partially dependent on VCP levels.
Another pathway for protein degradation -the endolysosomal pathway -has also been implicated in both dying back neurodegenerative diseases and neurite remodeling. Three recent studies focusing on neurite pruning in Drosophila have found that the endosomal sorting complex required for transport (ESCRT)-III is cell-autonomously required for neurite pruning [67] [68] [69] . While Zhang et al. [68] found that the endolysosomal pathway was important for downregulating the membrane-localized L1-type cell adhesion molecule neuroglian (Nrg) during dendrite pruning of da neurons, we found that endolysosomal downregulation of Patched was required for mushroom body axon pruning [67] . In contrast, Loncle et al. [69] provided evidence for a unique activity of the ESCRT-III complex, involving membrane remodeling to promote dendrite pruning in a mechanism that is independent of the endocytic machinery.
Dominantly inherited mutations in charged multivesicular body protein 2B (CHMP2B [70] ), a subunit of the ESCRT-III complex, have been identified in a small subset of ALS and FTD patients. The mechanism by which these mutations promote ALS is not currently known. Furthermore, dominant mutations in phosphatidylinositol 3,5-bisphosphate 5-phosphatase (encoded by FIG4) were also found in ALS [71] and in CMT type 4J [72, 73] patients. This is especially interesting as we have found that mutations in phosphatidylinositol 3-kinase class III (PI3K-CIII) inhibit axon pruning of mushroom body neurons [67] . The product of both PI3K-CIII-and FIG4-catalyzed reactions is phosphatidylinositol 3-phosphate, which recruits proteins containing a FYVE domain to endosomal membranes and affects vesicle trafficking.
Two GTPases that regulate endocytosis are mutated in CMT -Rab7 and dynamin 2 (DMN2). The small GTPase Rab7 regulates membrane trafficking during the maturation of the early endosome to the late multivesicular endosome and also the subsequent maturation to the lysosome. CMT2-causing mutations in Rab7 are inherited in a dominant fashion. However, studies in cultured neurons and cell lines suggest that the mutant forms of Rab7 that cause CMT are actually fully functional [74, 75] . Moreover, these studies show that these Rab7 mutants are found largely in the GTP-bound (i.e. active) state and that they can drastically reduce the cell-surface expression of the neurotrophin receptor TrkA [74, 75] . Lastly, mutant Rab7-positive vesicles appear more active because they pause less frequently than wild-type vesicles when travelling along the axon [76] . Therefore, hyperactivation of Rab7-regulated endocytosis/trafficking may play a part in promoting CMT. DMN2 is a large GTPase that is involved in clathrin-mediated endocytosis. Mutations in DMN2 have been discovered both in centronuclear myopathies (CME) and CMT; while the CME-causing mutations were suggested to be hypermorphic, the CMT mutations were found to be hypomorphic [77, 78] . Interestingly, cell-autonomous expression of a temperature-sensitive allele of the Drosophila dynamin gene, shibire(ts1), results in pruning defects [67] .
Taken together, it seems that protein degradation via the UPS and endolysosomal pathways seems to be central to both neuronal remodeling and dying back neurodegenerative diseases ( Figure 2 ). Whether this indicates common mechanisms is questionable, especially as both pathways serve 'housekeeping' functions. The mechanisms by which these protein degradation pathways regulate developmental and pathological axon elimination are just beginning to be clarified and therefore more work is necessary to uncover the underlying similarities and differences. These should in turn provide hints regarding the existence of convergent mechanisms underlying neurite degeneration during development and in dying back neurodegeneration. Caspase Activation Caspases are best known as critical regulators of cell death by apoptosis. As such, caspase activation has been proposed as a possible mechanism to trigger neuronal cell death in ALS and in other dying back neurodegenerative diseases. Indeed, caspase activation has been observed in samples from deceased ALS patients [79] and in some, but not all, SOD1 mouse models [80, 81] . Manipulating caspase activity by genetic or pharmacological means only slightly improved viability and delayed the onset of neurodegeneration in SOD1 transgenic mice [80, 82] . A recent study revealed that deleting the proapoptotic Bcl-2 family protein Bax indeed blocked the cell death of motor neurons expressing mutant SOD1 but only slightly delayed motor neuron denervation [83] . In this study, the authors also identified a delay in events occurring after denervation, such as gliosis, suggesting that Bax has additional non-apoptotic functions. Conditional deletion of both Bax and another Bcl-2 family member, Bak, in the central nervous system resulted in a more impressive suppression of both neurodegeneration and ALS-like symptoms in SOD1 transgenic mice [84] . Interestingly, upregulation of the anti-apoptotic protein Bcl2a1-a has been observed at the early stages of axonal loss and before neuronal death in the SOD1 mouse model [51] . This upregulation is clearly not sufficient to protect against axon degeneration but it seems to suggest that the neurons aim to overcome an aberrant activation of the apoptotic system to circumvent cell death or axonal degeneration.
Thus, the role of the apoptotic machinery in the SOD1 model has yielded confusing results, but, in sum, these findings suggest that, in addition to promoting cell death at the final stages of the disease, the apoptotic machinery may play crucial roles in the early stages of axonal atrophy. Surprisingly, to the best of our knowledge, the role of caspases or other apoptotic components has not been examined in more recent models of ALS.
Type I diabetes can be induced in rats by treatment with streptozotocin, which eliminates the insulin-producing pancreatic b-cells. Using this model Cheng and Zochodne [85] have demonstrated that caspase-3 is activated in sensory axons and cell bodies of diabetic rats; despite caspase-3 activation, however, the neurons did not undergo cell death in this model. In vitro models of dorsal root ganglion neurons treated with the neuropathic agent cisplatin exhibit reduced axonal outgrowth, which is accompanied by a Bax-dependent activation of apoptosis [86, 87] . Intriguingly, Bax is also a critical regulator of axonal pruning, where it is required for local caspase activation [88, 89] . Finally, mice lacking Bcl-w (also known as Bcl2l2) exhibit peripheral neuropathy as a result of axonopathy without cell death [90] , and the authors also found that Bcl-w is the only Bcl-2 family member that is enriched in axons. Taken together, these experiments provide strong evidence that axonal activation of the apoptotic machinery can cause peripheral neuropathy.
While neuronal remodeling does not involve cell death, the roles of numerous components of the apoptotic machinery have been highlighted in various systems [91] . A transgenic reporter for caspase activation has allowed for the observation of local caspase activation during dendrite pruning of Drosophila da neurons [54] . Genetic experiments confirmed that the initiator caspase Dronc (the Drosophila caspase-9 ortholog) is cell autonomously required for dendrite pruning [53, 54] . Dronc activation is mediated by the degradation of its inhibitor DIAP1 [53] via the UPS. In mammals, caspase-3, -6 and -9 were shown to be required for trophic-deprivation-mediated axon fragmentation of sensory and sympathetic neurons and, similar to the situation in flies, XIAP1 was suggested to inhibit caspase-3 activity [44, 89, 92, 93] . Caspase-3 and -6 also regulate developmental pruning of retinal connections in the superior colliculus [44] . In both mammals and flies, the mechanism by which caspase activation spares the death of the neuron and how localized activation is achieved are not well understood. It is worth noting that non-apoptotic functions for the apoptotic machinery in a wide range of vital cellular processes have been shown to occur at subthreshold levels that do not activate cell death [94] [95] [96] . Importantly, the studies on the role of the apoptotic system in the axonal pruning have pointed out that, although cell death and pruning share many elements, they are not identical [91, 97] .
What could be the underlying cause for the activation of the axonal apoptotic system in dying back neurodegeneration? The prime suspect is mitochondrial damage and dysfunction and the consequent cellular energy crisis [98] . Indeed, locally induced mitochondrial damage results in local caspase activation, leading to dendrite pruning of hippocampal cultured neurons [99] . Furthermore, mitochondria are affected in almost all forms of peripheral neuropathy. Abnormal mitochondria in sensory neurons and axons were detected in murine models of both type I and type II diabetes [100, 101] . Several chemotherapy drugs such as cisplatin and oxaliplatin generate DNA damage and impair mitochondrial function [102] . The taxane family of chemotherapeutics functions by inhibiting tubulin dynamics, which then leads to impaired mitochondrial trafficking in axons and subsequently to the accumulation of damaged mitochondria [103] . These damaged mitochondria exhibit increased calcium permeability that can result in activation of the apoptotic system. Mitochondrial dysfunction is strongly associated with some cases of CMT as well. Mutations in the mitochondrial proteins ganglioside-induced differentiation-associated protein 1 (GDAP1) and mitofusin 2 (Mfn2) account for different forms of CMT, including the most severe cases of CMT2. In both cases, the mutations are associated with impaired mitochondrial activity and calcium homeostasis, and accumulation of defective mitochondria in axons [104, 105] .
In ALS, accumulating evidence points to mitochondria playing a wider role in the maintenance of neuronal health, possibly related to trafficking. The aberrant activity and localization of mutant SOD1 can directly affect mitochondrial health and function. Three mechanisms that may play a part in SOD1-related mitochondria toxicity are: translocation of SOD1 into the intermembrane space; control of SOD1 activity within the intermembrane space; and altered mitochondrial permeability [106, 107] .
An additional potential role for mitochondria relates to calcium. Impaired calcium homeostasis, sometimes combined with caspase activation, is known to result in activation of calciumdependent proteases known as calpains through the degradation of their axonal intrinsic inhibitor calpastatin. Calpains were found to regulate developmental pruning of retinal ganglion cell axons and axon degeneration in response to trophic deprivation [108] . Furthermore, calcium transients appear to precede dendrite pruning of Drosophila da neurons, which likely involves calpain activation [109] . In agreement, calpain inhibition seems to protect against chemotherapy-induced neuropathy [110] .
Overall, we think that the accumulating evidence for nonapoptotic functions of caspases during neuronal remodeling and other cellular processes warrants a re-investigation of the role of caspase activation during the early phases of dying back neurodegenerative diseases (Figure 2 ). New tools, such as reporters for caspase activity, as well as more refined and specific genetic perturbations should be useful in clarifying the role of caspases in dying back neurodegenerative diseases.
Neuron-Glia Interactions
Neuroinflammation is a hallmark of many neurodegenerative diseases including ALS [111, 112] and is mostly a consequence of the function of activated microglia and astrocytes, suggesting that these cells might play an active role in the progression of dying back neurodegenerative diseases. To explore the possible contribution of non-cell-autonomous factors, Clement et al. [113] created chimeric SOD1 mouse models: in these animals, only some of the cells expressed mutant SOD1 while other cells were wild type. Indeed, the existence of non-neuronal wildtype cells resulted in extended survival of these ALS mouse models [113] . Furthermore, via tissue-specific deletion of the mutant SOD1 gene, Boillé e et al. [114] created a mouse model in which mutant SOD1 expression was exclusively eliminated from microglia. Interestingly, they found that, while the onset of neurodegeneration was not affected by excising the mutant SOD1 gene in microglia [114] , or in astrocytes [115] , disease progression was significantly delayed, suggesting that microglia and astrocytes play a crucial role in disease progression. Finally, mouse astrocytes expressing mutant SOD1 as well as ALS patient-derived astrocytes were shown to secrete toxic factors that specifically affect motor neurons [116, 117] .
Another link to the potential role of astrocytes in ALS progression is the fact that expression of the excitatory amino acid transporter 2 (EAAT2), which is primarily expressed in astrocytes, is reduced in ALS patients as well as in other neurodegenerative diseases [118] . Reduced activity of glial EAAT2 might lead to increased neuronal glutamatergic excitotoxicity. Indeed, driving the expression of transgenic EAAT2 delays the onset of ALS in SOD1 mouse models [119] . Therefore, it seems that SOD1 mutant glia might play a dual role in disease progression: on one hand, they seem to provide less protection against excitotoxicity but, on the other, they seem to actively secrete toxic factors [120] .
Glia-neuron interactions also play important roles during neuronal remodeling. In mammals, glia are required for smallscale synapse remodeling [121] . Microglia play a key role in synapse elimination in the hippocampus [122] and in the thalamus [123] . Recently, it was reported that astrocytes are also required for normal synapse remodeling in the thalamus [124] , suggesting that microglia and astrocytes complement each other's function. In Drosophila, glia have been implicated in multiple steps of neuronal remodeling. First, an elegant study has found that cortex glia instruct mushroom body axon pruning by secreting the transforming growth factor b ligand myoglianin [125] . Second, fragments of mushroom body axons are engulfed by glia and processed by the lysosomal degradation pathway [126, 127] . A later study reported that fragment engulfment depends on glial expression of the engulfment receptor Draper (the Drosophila CED-1 ortholog) [126] [127] [128] [129] . Recently, it was shown that astrocytes are the main glial type required for fragment clearance, despite their low numbers compared with other glial cells [130, 131] .
Given the critical role of mammalian Schwann cells for the metabolic homeostasis and maintenance of peripheral axons through trophic support and myelination, it comes as no surprise that Schwann cell dysfunction contributes to peripheral neuropathy. CMT1 mostly results from mutations in myelinassociated genes, such as peripheral myelin protein 22 (PMP22) and myelin protein zero (MPZ): for a more comprehensive list, see [25, 132] . Likewise, other genetic lesions or a toxic neuropathic environment that directly damages the nerve might also be deleterious to the Schwann cell, resulting in defects in both cell types. The contribution and crosstalk of the neuronal and glial defects in neuropathies are not well understood [25] .
The fact that glia-neuron interactions play key roles in both neurodegenerative diseases and developmental remodeling (Figure 2 ) is perhaps not surprising and does not in itself provide evidence for convergent mechanisms. However, the finding that intimate neuron-glia communication affects both development and disease highlights the importance of future mechanistic studies to uncover common mechanisms. For example, recent work has shown that microglia mediate early synapse loss in Alzheimer's disease mouse models by similar molecular mechanisms to those used by microglia in developmental synapse pruning [133, 134] . Balance between Degeneration and Regenerative Forces In his seminal review from 1964, Cavanagh wrote: ''.the clinical consequences are seen only when the compensatory forces begin to fail in the face of cumulative nerve fiber damage'' [27] . What are these compensatory forces and are they involved in a 'tug-of-war' with degenerative forces?
This proposed tug-of-war predicts that the failure of compensatory pathways should hasten and promote disease progression. Indeed, axonal regeneration in response to capsaicininduced denervation of sensory axons was reduced in diabetic patients [135] . Likewise, in vitro studies using tissues from diabetic or healthy mice have suggested that the levels of skinderived axon growth factors, other than NGF, decrease soon after diabetes induction, providing another potential mechanism for the reduced growth potential of these neurons [136] . Finally, ALS-causing mutations in the actin regulator profilin-1 have been identified in human patients [137] . Profilin-1 promotes actin nucleation and therefore plays multiple roles during neuronal development, including axon growth [138] . Interestingly, axonal transport of Drosophila profilin mRNA (chic) is required for developmental axon regrowth of mushroom body neurons [139] .
Axon-repulsive cues that restrict axonal growth and induce pruning during development may inhibit the regenerative response as well. An elegant study that began by screening for modifiers of ALS in a zebrafish model but extended the findings to human patients found that Eph receptor A4 (EphA4) expression is negatively correlated with disease onset and progression [140] . Eph receptors mediate axon repulsion in response to ligands from the ephrin family and also induce pruning of hippocampal axons during development [141, 142] . Indeed, neurons that express high levels of EphA4 show high susceptibility to ALS-causing mutations. Remarkably, depletion of EphA4 in animal models confers relative resistance to ALS and delays disease onset [140] . Another receptor-ligand pair involved in axon repulsion -plexin-semaphorin -is known to repel sensory axons and to induce the developmental axon pruning of corticospinal and hippocampal axons [143, 144] . Semaphorins are also expressed in the adult skin and inhibit growth of sensory axons under pathological conditions [145] . Therefore, receptors of repellent guidance molecules such as the semaphorins and ephrins may play a role in both developmental remodeling and dying back neurodegeneration.
Nitric oxide (NO) could be an additional player in this tug-ofwar. NO is secreted from both microglia and astrocytes [146] and its levels may rise following mitochondrial dysfunction, which is highly prevalent in neuropathy as discussed above. NO has been proposed to promote neurodegeneration by multiple possible mechanisms, including S-nitrosylation of various proteins [147, 148] . However, low levels of NO support viability and promote growth [147] [148] [149] . Recent work has revealed that NO levels function as a switching mechanism between pruning and regrowth of mushroom body axons in Drosophila [150] : while high NO levels promote pruning by a mechanism that is not well understood, NO levels drop rapidly to facilitate developmental axon regrowth via a nuclear receptor complex and the target of rapamycin (TOR) pathway. The mammalian TOR (mTOR) complex also positively regulates axon regeneration following injury in mammals [151] . In addition, mTOR protects motor neurons expressing mutant SOD1 [152] . Therefore, mechanisms that promote developmental axon regrowth and regeneration following injury might provide protection to neurons exposed to toxic and pathological conditions. Whether this tug-of-war reflects a genuine convergence between remodeling and diseasemediated neurodegeneration remains to be mechanistically investigated.
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Concluding Remarks
While there has been significant progress in understanding the genetic basis of several dying back neurodegenerative diseases, such as ALS and peripheral neuropathies, the mechanistic features of these diseases remain mostly unknown. Many of the disease mutations are dominantly inherited and therefore might result in a gain-of-function defect. Likewise, expression of disease-associated mutants in vertebrate and invertebrate models has provided many insights but has not yet been instrumental in providing a mechanistic understanding of these diseases. One reason is that, in these models, the mutant genes are often expressed at non-physiological levels, which might result in pleiotropic defects, thus making it difficult to identify the causal events leading to the disease.
The field of developmental neuronal remodeling has expanded significantly in recent years; many new models have been employed and new concepts and mechanistic understanding have emerged. Nevertheless, we still have much to explore and discover before we can begin to format a comprehensive view of the mechanisms underlying remodeling. Most importantly, a mechanistic understanding of how axons are dismantled during development is still lacking.
In this article, we have explored potential convergence points between what we know about mechanisms regulating developmental remodeling and those associated with dying back neurodegenerative diseases. Uncovering the mechanisms that drive pathological neurodegeneration during disease is highly challenging. One of the reasons is the fact that disease-causing mutations are complex, involving cell-autonomous and noncell-autonomous effects. Additionally, the disease-causing mutations must be viable in order for the organism, or patient, to undergo normal development and therefore often do not reflect a complete loss-of-function but rather hypomorphic mutations or gain-of-function mutations. This means that mutations can be subtle in nature and their effect sometimes counterintuitive, especially when involving 'housekeeping' genes, complicating the interpretation of the underlying mechanisms. Furthermore, pathological processes are by nature much less stereotypical than developmental processes.
In contrast to disease, developmental remodeling is almost exclusively studied in genetic model organisms under controlled conditions. Also, studying neuronal remodeling involves looking for genes that are required for degeneration, quite the opposite from approaches in disease-oriented research. In other words, those studying disease in this context largely focus on spontaneous mutations that cause neurodegeneration, while those studying developmental remodeling largely focus on genetic perturbations that inhibit degeneration. We believe that these differences are at the core of the limited intellectual exchange between the disease-associated and developmental axon elimination field, and also highlight the potential value of more crosstalk between developmental and disease-oriented studies. While the similarities discussed in this review are often circumstantial and speculative, we think that there is ample evidence that common mechanisms at certain stages are at least possible. Taken together, we believe that mechanisms that have evolved to dismantle axons and dendrites during normal development have the potential to shed new light on what happens when neuronal structure is compromised during disease and vice versa. Therefore, we believe that more extensive communication between the two fields holds the potential for significant breakthroughs in both.
